KRAS and lung adenocarcinoma: In addition, it was reported that specific KRAS mutations could affect the immune microenvironment of lung adenocarcinoma patients, which affect the efficacy of immune checkpoint inhibitors, implying stratification of patients for immunotherapy should be tailored based on the specific mutant KRAS variants and tumor microenvironment24.